<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543539</url>
  </required_header>
  <id_info>
    <org_study_id>IN.PACT™ AV Access PAS002</org_study_id>
    <nct_id>NCT04543539</nct_id>
  </id_info>
  <brief_title>IN.PACT™ AV Access Post-Approval Study (PAS002)</brief_title>
  <official_title>IN.PACT™ AV Access Post-Approval Study (PAS002)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term safety will be summarized&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of the IN.PACT™ AV Access Drug&#xD;
      Coated Balloon (DCB) for treatment of subjects presenting with de novo or non-stented&#xD;
      restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper&#xD;
      extremity. Patients will be followed for five years. The IN.PACT™ AV Access PAS 002 is&#xD;
      required by the Food and Drug Administration (FDA) as a condition of product approval. This&#xD;
      study is conducted within Medtronic's post market surveillance platform.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Infection and Infestations Serious Adverse Events</measure>
    <time_frame>Through 12 months post-index procedure</time_frame>
    <description>Demonstrate Infection and Infestations Serious Adverse Events, including pneumonia, meets the performance goal of 30% in the primary cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>Through 1, 2, 3, 4, and 5 years post-index procedure</time_frame>
    <description>Determine mortality rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Extended Cohort - Characterize Infections and Infestations Serious Adverse Events</measure>
    <time_frame>Through 1-year and all-cause mortality through 5-years post-index procedure</time_frame>
    <description>Characterize infections and infestations Serious Adverse Events, including pneumonia.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <condition>Arteriovenous Fistula Stenosis</condition>
  <condition>Arteriovenous Fistula Occlusion</condition>
  <condition>Fistula</condition>
  <arm_group>
    <arm_group_label>IN.PACT™ AV Access PAS Primary Cohort</arm_group_label>
    <description>The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN.PACT™ AV Access PAS Extended Cohort</arm_group_label>
    <description>The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort</intervention_name>
    <description>For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.</description>
    <arm_group_label>IN.PACT™ AV Access PAS Primary Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort</intervention_name>
    <description>For treatment of stenosis in the AV circuit</description>
    <arm_group_label>IN.PACT™ AV Access PAS Extended Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients that will have an angioplasty with the IN.PACT™ AV&#xD;
        Paclitaxel-Coated PTA Balloon Catheter (IN.PACT™ AV DCB).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Primary Cohort Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥ 21 years of age&#xD;
&#xD;
          -  Patient has a mature native AV fistula created ≥ 60 days prior to the index procedure&#xD;
&#xD;
          -  Patient has a de novo and/or non-stented restenotic lesion located between the&#xD;
             arteriovenous anastomosis and axillosubclavian junction&#xD;
&#xD;
          -  Patient has a target lesion or a tandem lesion that is ≤ 100 mm in length (by visual&#xD;
             estimate) Note: Tandem lesions may be included provided they meet all of the following&#xD;
             criteria: a. Separated by a gap of ≤ 30 mm (3 cm), b. Total combined lesion length,&#xD;
             including 30 mm gap, ≤ 100 mm, c. Able to be treated as a single lesion&#xD;
&#xD;
          -  Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate)&#xD;
&#xD;
          -  Patient underwent successful crossing of the target lesion with the guide wire and&#xD;
             pre-dilatation with a PTA balloon defined as: Residual stenosis of ≤ 30% AND Absence&#xD;
             of a flow limiting dissection or perforation AND No extravasation requiring treatment&#xD;
&#xD;
        Primary Cohort Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant, or are intending to become pregnant, or men&#xD;
             intending to father children&#xD;
&#xD;
          -  Patient is receiving immunosuppressive therapy&#xD;
&#xD;
          -  Patient has an infected AV access or systemic infection&#xD;
&#xD;
          -  Patient with hemodynamically significant central venous stenoses that cannot be&#xD;
             successfully treated prior to treatment of the target lesion&#xD;
&#xD;
          -  Patient with target lesion located central to the axillosubclavian junction&#xD;
&#xD;
          -  Patient has significant arterial inflow lesion requiring treatment more than 2 cm&#xD;
             upstream from the anastomosis in the AV access&#xD;
&#xD;
          -  Patient has presence of pseudoaneurysm or aneurysm requiring treatment at the lesion&#xD;
             site&#xD;
&#xD;
          -  Target lesion is located within a bare metal or covered stent&#xD;
&#xD;
          -  Patients with known allergies or sensitivities to paclitaxel&#xD;
&#xD;
          -  Patient with known contraindication, including allergic reaction, or sensitivity to&#xD;
             contrast material that cannot be adequately pre-treated&#xD;
&#xD;
          -  Patient who cannot receive recommended antiplatelet and/or anticoagulant therapy&#xD;
&#xD;
          -  Patient is enrolled in another investigational drug, device, or biologic study and has&#xD;
             not completed the primary endpoint, or was previously enrolled in this study&#xD;
&#xD;
          -  Patient has a co-morbid condition that, in the judgment of the Investigator, may cause&#xD;
             him/her to be non-compliant with the protocol or confound the data interpretation&#xD;
&#xD;
          -  Patient has an active COVID-19 infection or relevant history of COVID-19&#xD;
&#xD;
        Inclusion Criteria for Extended Cohort:&#xD;
&#xD;
          -  Patient is ≥ 21 years of age&#xD;
&#xD;
        Exclusion Criteria for Extended Cohort:&#xD;
&#xD;
          -  Patient has an active COVID-19 infection or relevant history of COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PSR Study Team</last_name>
    <phone>763-526-5668</phone>
    <email>rs.productsurveillanceregistry@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Dalman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Bernardo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventionals</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Kafie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mel Sharafuddin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rundback, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Hnanth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Kramer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

